According to a recent retrospective multicenter and SEER database study concerning 642 de novo ATCs and 47 ATCs with a DTC component, no statistical differences in survival or clinical course were demonstrated, however, BRAF mutation was expressed more often than RAS in tumors progressing from DTC [143]. Here, BRAF is linked to Ehlers-Danlos syndrome, musculocontractural type.